Cormorant Asset Management LLC Position in Portola Pharmaceuticals INC (PTLA) Has Cut as Market Value Rose

March 14, 2018 - By Vivian Currie

Investors sentiment increased to 2.16 in 2017 Q3. Its up 0.85, from 1.31 in 2017Q2. It improved, as 20 investors sold PTLA shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Credit Suisse Ag accumulated 141,369 shares. Cadian Capital Management LP has invested 2.95% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Us Bancorp De holds 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 42,849 shares. Guggenheim Capital Ltd Liability Co invested in 120,362 shares. Manufacturers Life Insurance Company The invested in 0% or 41,900 shares. First Tru Advsr Ltd Partnership reported 43,259 shares. Balyasny Asset Mngmt Ltd Com accumulated 5,300 shares. 577,565 are held by Zevenbergen Capital Invs Limited Liability. Gideon Cap Advisors Incorporated holds 0.29% or 5,433 shares in its portfolio. State Street Corp owns 2.40M shares. Fisher Asset Management Limited Liability Corp reported 61,893 shares stake. Cormorant Asset Mngmt Limited Liability accumulated 500,000 shares. 947 are held by First Quadrant LP Ca. Employees Retirement Association Of Colorado holds 0% or 11,029 shares in its portfolio. Emerald Advisers Pa has 453,921 shares for 1% of their portfolio.

Since December 15, 2017, it had 0 insider buys, and 1 sale for $563,950 activity.

Cormorant Asset Management Llc decreased its stake in Portola Pharmaceuticals Inc (PTLA) by 44.44% based on its latest 2017Q3 regulatory filing with the SEC. Cormorant Asset Management Llc sold 400,000 shares as the company’s stock rose 22.73% with the market. The hedge fund held 500,000 shares of the health care company at the end of 2017Q3, valued at $27.02 million, down from 900,000 at the end of the previous reported quarter. Cormorant Asset Management Llc who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be less bullish one the $2.40B market cap company. The stock increased 0.69% or $0.25 during the last trading session, reaching $36.7. About 629,758 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since March 14, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Cormorant Asset Management Llc, which manages about $841.40 million and $566.36 million US Long portfolio, upped its stake in Myokardia Inc by 71,889 shares to 1.07M shares, valued at $45.93M in 2017Q3, according to the filing. It also increased its holding in Ignyta Inc (NASDAQ:RXDX) by 2.00 million shares in the quarter, for a total of 3.50 million shares, and has risen its stake in G1 Therapeutics Inc..

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on May, 14. They expect $-1.54 earnings per share, down 108.11 % or $0.80 from last year’s $-0.74 per share. After $-1.41 actual earnings per share reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 9.22 % negative EPS growth.

More recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: which released: “Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump March 12, 2018” on March 12, 2018. Also published the news titled: “Portola Pharma (PTLA) Announces New Interim Results from Ongoing ANNEXA-4 …” on March 12, 2018.‘s news article titled: “Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for …” with publication date: February 20, 2018 was also an interesting one.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 7 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Portola Pharmaceuticals has $81 highest and $24 lowest target. $69.50’s average target is 89.37% above currents $36.7 stock price. Portola Pharmaceuticals had 38 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 5. Citigroup maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Friday, May 27. Citigroup has “Buy” rating and $36 target. Credit Suisse maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Tuesday, March 13. Credit Suisse has “Outperform” rating and $49 target. The company was upgraded on Thursday, August 24 by Credit Suisse. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, December 27 report. Oppenheimer maintained the stock with “Buy” rating in Monday, January 15 report. The company was maintained on Wednesday, August 9 by Cowen & Co. The firm has “Outperform” rating given on Monday, March 28 by Credit Suisse. The firm has “Outperform” rating given on Friday, February 24 by Oppenheimer. The rating was maintained by Oppenheimer with “Buy” on Tuesday, December 19.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: